Evaluation of a Best-Practice Advisory for Primary Aldosteronism Screening
Authors' conclusion
The study results suggest that noninterruptive BPAs are potentially promising PA screening-assistance tools, particularly among primary care physicians.
Study context
- Population
- Adults with hypertension and ≥1 of: ≥4 antihypertensive medications, hypokalemia, age <35 years, or adrenal nodule(s); not previously tested for primary aldosteronism (PA)
- Participants
- 14,603 unique candidates
- Outcome
- Number of PA screening candidates identified by the BPA; PA screening rates; BPA use patterns by physician specialty
- Follow-up
- October 1, 2021, to December 31, 2022
Methodological detailsacademic centre outpatient clinics
- Academic centre outpatient clinics
Main finding
As reported in the abstract
PA screening via noninterruptive BPA · 15 months
- Unique candidates identified
- 14 603
- Received PA screening orders
- 2040 (14.0%)
- Completed recommended screening, of those ordered
- 1439 (70.5%)
- Positive screening results
- 250 (17.4%)
- Screening orders placed by internists
- 40.0%
- Screening orders placed by family medicine physicians
- 28.1%
- Orders via embedded order set, family practitioners
- 80.3%
- Orders via embedded order set, internists
- 68.9%
- Orders placed outside the best-practice advisory (BPA), specialists
- 83.0%-95.4%
Observational data: associations, not effects.
Further findings
Characteristics of screened vs unscreened patients
- Screened patients were younger and included more women and Black patients
- Screening more likely with obesity and dyslipidemia; less likely with CKD and established CV complications
Original publication
Evaluation of a Best-Practice Advisory for Primary Aldosteronism Screening. JAMA Intern Med. Published 1 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →